SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)-- Regulatory News:

MEDIAN Technologies (Paris:ALMDT), the Imaging Phenomics Company®, announced today that it will participate in The Liver Meeting®, the annual meeting of the Association for the Study of Liver Diseases (AASLD) October 20-24 at the Walter E. Washington Convention Center, Washington DC, USA. The industry exhibition will be opened from Oct 21^st to Oct. 23^rd. The company’s scientific and business team will demonstrate Median’s imaging phenomics platform iBiopsy® at booth #241.

iBiopsy® is Median’s investigational platform designed to acquire, index, and analyze imaging phenomics, decoding disease biomarkers from standard medical images. iBiopsy® is at the core of precision and predictive medicine, providing insights into the development of novel therapies and individualized treatment strategies. The first application of iBiopsy® is for the assessment of Nonalcoholic Steatohepatitis (NASH), a liver disease which is dramatically increasing in prevalence in all parts of the world.

iBiopsy® is also the backbone of Median’s innovative development efforts and combines the latest advances in artificial intelligence (AI) and big data predictive analytics to harness the power of imaging phenomics. Because of its leading role within the field of imaging phenomics, Median Technologies is proud to announce that “The Imaging Phenomics Company®” is now a registered trademark of Median Technologies.

The Liver Meeting® is organized every year by the American Association for the Study of Liver Diseases (AASLD) and is the premier conference in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies. More information about The Liver Meeting® is here: https://www.aasld.org/events-professional-development/liver-meeting.

The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017. Median Technologies has been awarded the 2017 Tech 40 Label and has joined the EnterNext Tech 40 Index. Median is a member of the Bpifrance Excellence Network. For more information: www.mediantechnologies.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20171017005817/en/